PRIVATE clinical-stage
biotherapeutics company, Jennerex,
has entered into a partnership with
bio-pharmaceutical company
Transgene to develop and
commercialise JX-594 for the
treatment of solid tumors in
Europe, the Commonwealth and
the Middle East.
JX-594 is Jennerex’s lead cancer
biotherapeutic product, and has
shown anticancer activity and a
well tolerated safety profile in Phase
1 and Phase 2 clinical trials to date.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.